Adaptive Biotechnologies highlights MRD testing role in new myeloma cure definition from International Myeloma Society

• Adaptive Biotechnologies highlighted a new International Myeloma Society consensus definition of multiple myeloma “cure” presented at the IMS annual meeting.
• The framework centers on sustained MRD-negative status over time, positioning highly sensitive MRD testing as a gatekeeper for cure designation.
• The criteria could expand routine use of the company’s clonoSEQ assay in long-term monitoring, strengthening its role in standard myeloma care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250803PRIMZONEFULLFEED9834037) on September 25, 2026, and is solely responsible for the information contained therein.